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The goal: In everyday practice, we doctor often prescribe aspirin. The question arises whether this is 
always justified. It is necessary to discern the use of aspirin in primary prevention in people with no 
signs of cardiovascular disease from use in secondary prevention in at-risk individuals with previous 
heart attacks and strokes or known cardiovascular diseases (CVD). Coronary heart disease and stroke, 
the principal manifestations of CVD, are the first and second most common causes of death worldwide. 
The World Health Organization predicts that, by 2020, coronary heart disease will become the world’s 
most important cause of death and disability and, further, the most important cause of premature 
death, “if the victims of the COVID-19 pandemic do not overtake them” (authors comment). Low doses 
of aspirin were considered indispensable in the prevention of heart attack and stroke and other CVD. 
New guidelines, though, suggest that aspirin should not be prescribed to most adults who are in good 
cardiovascular health and that the risk of internal bleeding often outweighs the benefit.
According to the European Guidelines for Cardiovascular Diseases and Prevention in 2016, using the 
experience of older historical trials, aspirin is recommended for the primary prevention of people with 
high CVD risk (especially those with a ten-year mortality risk of over 10%). The Antiplatelet Trialists 
Collaboration meta-analysis demonstrated the benefits of antithrombotic therapy (mainly aspirin) in 
patients with type 1 or type 2 DM with clinically established CAD, cerebrovascular disease or other 
forms of thrombotic disease, with a 25% reduction in risk of CV events.1
The use of aspirin for the primary prevention of CVD has been a subject of intense debate since the 
publication of three large, randomized clinical trials in 2018 (ASCEND, ARRIVE, and ASPREE). The 
American College of Cardiology and American Heart Association released the  new guidelines  in 
2019 and one of the mayor changes is recommendation against the broad use of aspirin in primary 
prevention.2 Low-dose aspirin 100 milligrams or less did not help older adults who do not have CVD. 
The new trials published 2019, meta-analysis of aspirin effects in primary prevention of CVD compris-
ing 13 randomized-controlled trials in 164.225 patents comparing aspirin versus placebo/control dur-
ing a mean follow-up period of 6.4 years suggested that the benefit of aspirin for primary prevention 
has been neutralized, perhaps due to the use of other modern preventive therapies, such as statins, and 
general improvements in the population prevalence of smoking and hypertension. The authors of the 
new guidelines said low-dose aspirin should not be routinely given as a preventive measure to adults 
70 years and older or to any adult who has an increased risk of bleeding. Aspirin did reduce CVD by a 
modest 11%, with a number needed to treat to prevent 1 event of 265, but it also increased major bleed-
ing, such as serious GI bleed, intracranial bleed or bleed needing hospitalization or transfusion by 43%. 
That is a number needed to harm of 210. Among major bleeding events, intracranial hemorrhage is 
associated with high mortality rates and functional dependency.3
Conclusion: Aspirin remains an important medication for acute management of vascular events; for 
use after certain procedures; for secondary prevention; and, only after careful selection of the right 
patients, for primary prevention.
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